Skip to main content

Latest news

Thu, 12/15/2016 - 17:00
  • Initially developed by TRANSGENE, one of ELSALYS BIOTECH’s founding shareholders, this antibody inhibits a deleterious subpopulation of

Tue, 02/16/2016 - 17:00
  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

Tue, 11/03/2015 - 17:00

IM Europe and Sofimac Partners are the main investors

 

Thu, 09/10/2015 - 17:00

Supported by ElsaLys Biotech, PX’Therapeutics, a subsidiary of the Aguettant group, and Centr

Thu, 07/02/2015 - 17:00
  • Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter